Related Experiment Videos
rhDNase in cystic fibrosis
1Regional Paediatric Cystic Fibrosis Unit, St James's University Hospital, Leeds.
British Journal of Hospital Medicine
|April 6, 1997
Summary
Cystic fibrosis (CF) patients may benefit from rhDNase therapy, which showed a 13% improvement in respiratory function. This review discusses optimal use of this new, costly treatment for CF lung disease.
Area of Science:
- Pulmonology
- Pharmacology
- Genetics
Background:
- Cystic fibrosis (CF) is a genetic disorder affecting approximately 1 in 2500 live births in the UK Caucasian population.
- Pulmonary involvement is a primary determinant of morbidity and mortality in CF patients.
- Current CF care strategies aim to manage symptoms and improve lung function.
Purpose of the Study:
- To review the efficacy and tolerability of recombinant human DNase (rhDNase) in cystic fibrosis (CF) care.
- To discuss the optimal utilization of rhDNase therapy, considering its cost and clinical benefits.
- To provide insights into integrating this novel therapy into existing CF treatment protocols.
Main Methods:
- Review of Phase 1, 2, and 3 clinical trials evaluating rhDNase in CF patients.
- Analysis of patient-reported outcomes and objective measures of respiratory function.
- Economic evaluation of rhDNase therapy in the context of CF management.
Main Results:
- rhDNase has demonstrated good tolerability in clinical trials.
- Patients treated with rhDNase showed an average initial increase in respiratory function of approximately 13% from baseline.
- The annual cost of a rhDNase prescription is approximately $7500.
Conclusions:
- rhDNase represents a significant advancement in cystic fibrosis therapy, offering measurable improvements in lung function.
- The high cost of rhDNase necessitates careful consideration for optimal patient selection and treatment strategies.
- Further research and clinical guidelines are needed to maximize the benefits of rhDNase for CF patients while managing healthcare resources.